Apotex has gotten a tentative nod from the US Food and Drug Administration (USFDA) for semaglutide. Meanwhile, Dr Reddy’s is awaiting the final approval for semaglutide in Canada.
Meanwhile, brokerage firm Citi has a ‘sell’ rating on the stock with a price target of ₹1,070 per share.The brokerage said the rejection prevents the company from participating in the initial wave of semaglutide in Brazil. Dr. Reddy’s has missed the early opportunity in a competitive market with 16 pending applications in Brazil, Citi’s note said.
Apotex’s tentative nod in the US suggest that it may gain a lead over Dr Reddy’s in Canada, the brokerage added.
Shares of Dr. Reddy’s Laboratories are looking to recover from the lows of the day, currently trading 1.8% lower at ₹1,213. The stock is down 5% in the last one month and as a result, has turned negative for the year.
Also Read: Wipro shares rise after $71 million deal; eyes growth in AI services

